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ABSTRACT Anorganismrequiresarangeofbiomoleculesforitsgrowth.Bydeﬁnition,theseareessentialmoleculeswhichconsti-
tutethebasicmetabolicrequirementsofanorganism.Asmallorganicmoleculewithchemicalsimilaritytothatofanessential
metabolitemaybindtotheenzymethatcatalyzesitsproductionandinhibitit,likelyresultinginthestasisordeathoftheorgan-
ism.Here,wereportahigh-throughputapproachforidentifyingessentialmetabolitesofanorganismusinggeneticandbio-
chemicalapproachesandthenimplementcomputationalapproachestoidentifymetabolitemimics.Wegeneratedandgeno-
typed 5,126 Mycobacterium tuberculosis mutants and performed a statistical analysis to determine putative essential genes. The
essential molecules of M. tuberculosis were classiﬁed as products of enzymes that are encoded by genes in this list. Although in-
complete, as many enzymes of M. tuberculosis have yet to be identiﬁed and characterized, this is the ﬁrst report of a large num-
ber of essential molecules of the organism. We identiﬁed essential metabolites of three distinct metabolic pathways in M. tuber-
culosisandselectedmoleculeswithchemicalsimilarityusingcheminformaticsstrategiesthatillustrateavarietyofdifferent
pharmacophores.Ourapproachisaimedatsystematicidentiﬁcationofessentialmoleculesandtheirmimicsasablueprintfor
development of effective chemical probes of M. tuberculosis metabolism, with the ultimate goal of seeking drugs that can kill this
pathogen.Asanillustrationofthisapproach,wereportthatcompoundsJFD01307SCand L-methionine-S-sulfoximine,which
share chemical similarity with an essential molecule of M. tuberculosis, inhibited the growth of this organism at micromolar
concentrations.
IMPORTANCE Theestimatethatmorelivesmayhavebeenlostin2009duetotuberculosis(TB)thaninanyyearinhistoryis
alarming.Approximately9.2millionnewcasesand1.8milliondeathsduetoTBwerereportedin2008.Thewidespreadpreva-
lence of Mycobacterium tuberculosis strains that are resistant to drugs currently used to treat TB means that new drugs are ur-
gentlyneededtotreattheseinfections.Here,wehaveidentiﬁedpathwaysforthebiosynthesisofessentialmetabolitesandassoci-
ated enzymes in M. tuberculosis using a genetics-based approach. Small molecules that mimic these essential metabolites were
identiﬁed, and some of them were shown to inhibit the growth of M. tuberculosis. Therefore, we illustrate an approach based on
geneticstodevelopinhibitorsthathavethepotentialtobeadvancedascandidatedrugsfortreatingTB.
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T
he availability of whole-genome sequences of bacterial patho-
gens was rapidly followed by high-throughput identiﬁcation
of genes essential for their proliferation. One of the main goals of
these studies was to identify proteins that could be targeted for
inhibitionofgrowth,withtheultimateaimofdevelopingdrugsto
treat infections with the pathogens. Mycobacterium tuberculosis is
the etiological agent of tuberculosis (TB), an infectious disease of
which ~9 million new cases and ~1.7 million mortalities were
reported for the year 2009 (1). Seminal studies of the global bur-
denofTBconductedbytheWHOhavedeclareddrug-susceptible
M. tuberculosis or readily treatable TB a global health emergency
(2,3).Newandeffectivedrugsarerequired,asexistingdrugshave
become suboptimal in many settings due to the requirement for
protracted periods of treatment and the emergence of multiple-
and extensively drug resistant strains of M. tuberculosis (4, 5).
Identiﬁcation of genes that encode essential proteins is a ﬁrst step
toward determining targets whose inhibition may result in the
arrest of growth or killing of M. tuberculosis.
In a seminal study, Sassetti and colleagues used a high-
throughput method based on a whole-genome microarray to
identify essential genes of M. tuberculosis by random mutagenesis
(6). This essential gene set of M. tuberculosis represents the basic
requirementforthegrowthandproliferationoftheorganismina
deﬁned medium in vitro. The availability of these data facilitated
further investigations to map the metabolic pathways and metab-
olites required by M. tuberculosis for proliferation. Given our fo-
RESEARCH ARTICLE
January/February 2011 Volume 2 Issue 1 e00301-10
® mbio.asm.org 1cusonthedevelopmentofdrugsagainstTBbasedontargetingthe
essential metabolic machinery of M. tuberculosis, we herein pro-
videaproofofconceptforhowonemaytransitionfromanessen-
tial gene to an enzyme to an essential metabolite to a potential
inhibitor of the enzyme with whole-cell viability.
M.tuberculosis,likeanyorganism,requiresanarrayofbiomol-
ecules for its survival. These biomolecules either are obtained
fromtheenvironmentoraresynthesizeddenovo.Anenzymethat
catalyzes the biosynthesis of an essential metabolite is itself essen-
tial, if we assume that there are no alternative enzymes or meta-
bolic pathways capable of synthesizing the same metabolite.
Therefore,inhibitingessentialenzymesisaneffectivewaytokillor
arrest the growth of an organism.
Many drugs that are highly successful in human clinical use
mimicasubstrateoraproductofessentialenzymes.Forexample,
folicacidisanessentialbiomoleculewhichneedstobesynthesized
de novo by many bacteria, and dihydropteroate synthase, an en-
zyme in the folic acid biosynthesis pathway, synthesizes dihydro-
folate from p-aminobenzoate (7). Sulfonamide-based drugs are
structuralanalogsofp-aminobenzoateandactbyinhibitingdihy-
dropteroate synthase (8). Many bacterial infections are effectively
treated with sulfonamides, as they mimic an essential substrate
and competitively inhibit an essential enzyme. Another well-
known class of drugs that mimics an essential biomolecule is the
-lactam group of antibiotics (9). They possess a core four-
memberedringthatmimicsthestructureoftheterminal D-alanyl-
D-alaninesubunitofthepeptidoglycanlayerinbacterialcellwalls.
This peptidoglycan layer is essential for the survival of bacteria, as
it is required for maintenance of cell structure (10). Transpepti-
dases required for cross-linking of peptide chains to network the
peptidoglycanlayeruseterminal D-alanyl-D-alanineasasubstrate.
By mimicking the natural substrate, -lactams engage the
transpeptidasesandinhibittheiractions,leadingtodestructionof
the peptidoglycan layer and the eventual death of the organism
(11).Therearenumerousotherexamplesofinhibitionofessential
enzymes by mimicking their substrates.
Inthisstudy,weidentiﬁedessentialmetabolitesofM.tubercu-
losis using the strategy summarized in Fig. 1. We began by identi-
fying genes and associated enzymes that are essential for the
growth and proliferation of the bacterium. For this we used the
Himar1 transposon to disrupt genes of M. tuberculosis. Nearly all
genes are susceptible to disruption, as the transposon requires
only the TA dinucleotide for insertion (12). The transposon is
delivered into M. tuberculosis cells using suicide mycobacterio-
phage, and the transduced mutants are obtained from drug-
containing plates (13, 14). A genome walking technique was used
to locate the site of transposon insertion and to determine the
identity of the disrupted gene (15). Genes whose disruptions do
not compromise the growth of the bacilli are classiﬁed as nones-
sential.
Our method is based on sequencing of the site of mutagenesis
to identify nonessential genes and, subsequently, the essential
genes (15). We then identify metabolites that are essential for the
growth and proliferation of M. tuberculosis as the products of re-
actionscatalyzedbyenzymesencodedbyessentialgenes.Ourcur-
rent collection contains 5,126 independent, genotyped, and ar-
chived mutants with disruptions in both intra- and intergenic
regions. A statistical analysis was performed to predict the essen-
tialityofthegenesthatwewereunabletodisrupt.Here,wereport
thatthepathwaysforpeptidoglycan,tetrapyrrole,andchorismate
biosynthesis are essential for the growth of M. tuberculosis. The
products of the enzymes that comprise these pathways are identi-
ﬁed as essential metabolites. We then discuss a cheminformatics
strategy to identify mimics of the essential M. tuberculosis metab-
olites that may be rational competitive inhibitors of the essential
enzymes and may thereby kill or inhibit the growth of M. tuber-
culosis. These mimics are starting points for further development
of molecules with increased-potency activity against M. tubercu-
losisforuseaschemicalprobesofmetabolismorasantitubercular
agents.
RESULTS
Identiﬁcation of nonessential and essential genes. We created a
libraryof5,126uniquetransposoninsertionmutantsofM.tuber-
culosis.Thiscollectionrepresentsthedisruptionandthereforeloss
offunctionof2,246uniquegenes.Aswewereabletoisolateviable
mutants, we deﬁne the genes disrupted in these mutants to be
nonessential for in vitro growth. In order to ensure that the func-
tion of any gene classiﬁed as nonessential was truly disrupted by
mutagenesis, all genes with far-distal insertions, as deﬁned by the
5= 80%/3= 100-bp test (which qualiﬁes a transposon insertion in
the proximal [5=] 80% of the gene or upstream of the distal [3=]
100 bp of the gene to be able to effectively disrupt the gene), were
excluded from the nonessential gene list (15). Two hundred
twelve genes were found with distal insertions and removed from
the nonessential gene list (see Table S1 in the supplemental mate-
rial).Similarly,ifadisruptedgenehadanisoenzymethatcatalyzed
thesamereaction,thefunctionofthedisruptedgenewouldnotbe
affected since the isoenzyme would carry out the reaction in the
mutant.Inthesecases,theidentiﬁcationofamutantwithasingle
insertion in a gene with an isoenzyme was irrelevant to whether
that gene’s function is essential for in vitro growth. Twenty-four
FIG 1 Schematic for identiﬁcation of essential molecules and their mimics.
The genome of an organism is mutagenized to saturation, and nonessential
geneswhoselossdoesnotcompromisetheabilityofanorganismtoproliferate
are identiﬁed. The genes whose loss could not be tolerated are essential and
code for essential proteins that have structural or regulatory functions or are
enzymes. The metabolite(s) that is produced by an essential enzyme is deter-
mined, and its molecular mimic(s) with pharmacological potential is identi-
ﬁed using cheminformatics. These mimics may bind to the essential enzyme,
inhibit its function, and eventually kill the organism.
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from the nonessential list. Finally, genes that were not disrupted
were reclassiﬁed as nonessential if they belonged to an operon
with an insertion proximal to the gene of interest due to a likely
polareffectonsuchgenes.Atotalof534nondisruptedgeneswere
classiﬁed as nonessential because their operons contained a prox-
imal insertion. This ﬁltering process thus left us with essential
genes under this speciﬁc in vitro growth condition.
The metabolic requirement and avail-
ability of nutrients during an infection
differ from the in vitro conditions that
were used to identify essential genes in
our study. Certain metabolites that have
to be synthesized de novo during growth
in vitro may be available in macrophages
or in the extracellular environment dur-
inganinfection,allowingtheorganismto
bypass the requirement to synthesize the
metabolites that may be identiﬁed as es-
sentialinourstudyandviceversa.There-
fore,ourmethodclearlydoesnotidentify
all the metabolites required for growth
and proliferation during an infection.
However, as our understanding grows
withrespecttohowthemetabolismofM.
tuberculosis changes given its environ-
ment, we anticipate application of our
methodology to derive state-speciﬁc es-
sential genes.
Deﬁnition of the essential molecules
of M. tuberculosis and exemplary path-
ways. Approximately 40% of M. tubercu-
losis genes are annotated as “hypotheti-
cal,” as they encode proteins whose
functions have yet to be characterized
(16). In this study, we focused on the
genes that encode enzymes with homol-
ogy to known enzymes, allowing facile
identiﬁcation of their products, which we
hereby deﬁne as essential metabolites. At
this time, we count 401 essential enzyme-
encoding genes of M. tuberculosis via our
genetic method, which should afford as
many nonredundant essential metabo-
lites of M. tuberculosis. Rather than ex-
haustively enumerate each of these, we
haveinsteadchosentodiscussthreepath-
ways where each of the steps processes an
essentialmetabolite,thushighlightingthe
critical role they play in M. tuberculosis
metabolism. Essential metabolites of
these pathways, namely, peptidoglycan,
chorismate, and tetrapyrrole biosynthe-
sis, their potential molecular mimics, and
their respective chemical similarities and
known pharmacological information are
presented(seeTableS2inthesupplemen-
tal material).
The peptidoglycan biosynthetic path-
way begins with an assembly of sugar and
amino acid residues to generate a disaccharyl-pentapeptide (or
tetrapeptide). The associated reactions occur internal to the
plasma membrane and are catalyzed by a series of enzymes. This
pathway and associated putative enzymes are shown in Fig. 2A.
ThecoreofthepathwaybeginswithconversionofUDP-N-acetyl-
D-glucosamine to UDP-N-acetyl-D-glucosamine-enol pyruvate
and ends with generation of disaccharyl-pentapeptide, GlcNAc-
MurNAc-L-Ala1-D-iGln2-mesoDapNH2
3-D-Ala4-D-Ala5 (17). Fig-
FIG2 (A)Genesandmetabolitesthatcomprisethepathwayforthebiosynthesisofthebuildingblocks
of peptidoglycan in M. tuberculosis; (B) composite of 23 genes of M. tuberculosis of the peptidoglycan
biosynthesis pathway (right) and a depiction of random loci with identical sizes and TA densities. The
arrows show the number of transposon insertions that each locus was able to sustain.
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withdenovobiosynthesisofaminoacidresiduesthatcomprisethe
pentapeptidechain.These23genesthatconstitutethepeptidogly-
can biosynthesis pathway contain a total of 416 eligible TA trans-
position sites that may be disrupted by the transposon. However,
none of these sites could sustain a viable insertion disruption, as
they were not represented among the 5,126 independent mutants
inourcollection.Figure2Bdepictsacompositelocusforallgenes
that comprise the peptidoglycan biosynthesis pathway and an-
other random locus that is identical in size and TA density. Ac-
cording to our mutagenesis data, the random locus sustained 36
transpositiondisruptions,whereasnonewereobservedintheloci
forthepeptidoglycanbiosynthesispathway.Weusedthesedatato
assess the essentiality of the pathway given that there are 63,956
total TA sites in the open reading frames of the M. tuberculosis
genome. The P value for the likelihood that the pathway for pep-
tidoglycan biosynthesis is essential is 3.52  1015. Therefore, we
concludethatthepathwayforpeptidoglycanbiosynthesisisessen-
tial for the growth and survival of M. tuberculosis. Disruption of
theabove-mentionedgenesthatconstitutethepeptidoglycanbio-
synthesis pathway was also not observed in a comprehensive mu-
tagenesis study undertaken by Sassetti et al. (6). The constituent
essential metabolites of this pathway are shown in Table 1.
The chorismate pathway is common to the biosynthesis of
L-tryptophan, L-tyrosine, and folic acid and consists of seven
genes, aroA to -C, -E, -G, -K, and -Q in M. tuberculosis. The aroC,
-K, -B, and -Q genes are located in a putative operon, while aroA,
-E, and -G are scattered around the genome. Each of these genes
has multiple TA sites and is thus susceptible to insertion disrup-
tion by Himar1 transposon. However, we were unable to isolate
viable mutants with disruption of any of these genes despite our
attempts, resulting in 5,126 unique mutants. Our statistical anal-
ysis for the probability of this observation yielded a P value of
0.007. Therefore, we conclude that the pathway for chorismate
biosynthesisisessentialforthesurvivalandgrowthofM.tubercu-
losis,anditsessentialmoleculesareshowninTable2.Itshouldbe
noted that a previous study showed that M. tuberculosis aroK is
essential, as the investigators were unable to isolate a mutant with
a deletion of this gene (18).
M.tuberculosispossessessixconservedgenesthatarededicated
totetrapyrrolebiosynthesis.ThegeneshemAto-D,hemL,andgltS
are located in three regions in the chromosome. The hemA to -D
genescompriseaputativeoperon.ThelocicontaininghemABCD,
adjacent genes, and the sites at which the Himar1 transposon has
inserted are shown (see Fig. S1 in the supplemental material).
None of the genes that comprise the tetrapyrrole biosynthesis
pathway have sustained a transposon insertion. The P value for
not observing a transposon insertion in any of the genes in our
collection of 5,126 genotyped mutations is 7  105. Therefore,
we conclude with high conﬁdence that the pathway for tetrapyr-
role biosynthesis is essential in M. tuberculosis. The essential mol-
ecules of this pathway are listed elsewhere (see Table S3 in the
supplemental material).
Searchformimicsofessentialmetabolitesusingcheminfor-
maticsstrategies.TheessentialmetabolitesofM.tuberculosisrep-
resent a signiﬁcant resource in the search for chemical probes/
tools of metabolism that may inspire novel antitubercular
therapeutics. While the speciﬁc biological activity of an essential
molecule is critical to these applications, in most cases, one ex-
pects a lack of drug-like properties to limit utility. A number of
strategiescanbeconsideredforidentifyingasetofmoredruggable
small molecules that mimic an essential molecule. Principally, all
strategiesshouldinvolveutilizationoftheneighborhoodprinciple
(19, 20), which states that structurally similar molecules should
exhibit similar properties and, in particular, biological activities.
Thisapproachhasbeenusedfrequentlyindrugdiscovery(21–24)
andinotherareas,suchastherapeuticdrugmonitoring(25).Dif-
ferent computational metrics may be used to assess the similarity
oftwomolecules,includingone-dimensional(1-D),2-D,and3-D
methods (24, 26). Quite simply, for example, one can use Tani-
motosimilarity(24)toﬁnd2-Dsimilarmoleculesmeetingagiven
level of similarity (the higher the better) to the identiﬁed essential
metabolite. Another approach is to generate a 3-D pharmacoph-
ore around a molecule (27), perhaps with some molecular shape
TABLE 1 Representative essential molecules of the peptidoglycan biosynthesis pathway in M. tuberculosis and their mimics
Essential molecule
Molecule ID, % similarity, MIC90 for M. tuberculosis (g/ml),
and structure of an analoga
UDP-GlcNAc-enol pyruvate 48239, 52, 0.237 351369, 57, 0.13
meso-Diaminopimelate 92585, 52, 0.21 341652, 62, 43
D-Alanyl-D-alanine 58257, 51 344159, 53, 29.5
a Representative essential molecules of the pathway for peptidoglycan biosynthesis in M. tuberculosis and examples of existing analogs. An identiﬁcation provided by the CDD
database (molecule ID), percent similarity to the corresponding essential molecule, and MIC90 for M. tuberculosis are shown. The MIC90 data are compiled in the CDD database
from various laboratories. The percent inhibition of molecule 58257 at a 10 M concentration was 8.98%.
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large multiconformer libraries of compounds. Examples of such
compound libraries to be searched could include molecules with
antitubercular activity, at the whole-cell and/or enzyme or target
level, such as those available in the Collaborative Drug Discovery
(CDD) TB database, consisting of many individual data sets of
compounds tested against TB, malaria, and other diseases (27,
28). Searching metabolite databases, such as the Kyoto Encyclo-
pedia of Genes and Genomes (KEGG) (29, 30) and LipidMaps
(31), or databases composed of commercially available molecules
like those found in ChemSpider (32), eMolecules, and ZINC (33)
could also be fruitful for identifying similar molecules for poten-
tial testing.
We have chosen for our ﬁrst attempts in essential molecule
mimicry to rely on 2-D Tanimoto similarity. The choice of Tani-
motosimilarityrestsnotonlyonitsrelativesimplicitybutalsoon
ourpreviouslyreportedﬁndingthatazaserinepotentlyinhibitsM.
tuberculosis glutamate synthase (GltB) (15). GltB is an essential
enzyme which catalyzes the formation of L-glutamate from
L-glutamineand2-ketoglutarate.Ananalysisofthe2-Dsimilarity
of L-glutamate and azaserine using the ChemAxon hashed-
ﬁngerprint methodology in the CDD TB database yields a Tani-
motovalueof33%.Wehypothesizedthatazaserinemaybindand
inhibit glutamate synthase by mimicking the natural substrate of
this enzyme. In order to test this hypothesis, we created an M.
tuberculosisstrainoverexpressinggltBanddeterminedtheMICof
azaserine using the broth dilution method (34). Quantitative re-
versetranscription-PCR(RT-PCR)revealeda3.2-foldincreasein
the expression of gltB in the recombinant strain overexpressing
this gene. The MICs for wild-type M. tuberculosis CDC1551 and
the strain overexpressing gltB were 0.25 to 0.5 g/ml and 1.0 to
2.0 g/ml, respectively. As a control, we also determined the MIC
of isoniazid, as GltB is not known to be the target for this drug;
wild-type M. tuberculosis CDC1551 and gltB-overexpressing
strains exhibited identical susceptibilities (MICs of 0.03 to
0.06 g/ml). While overexpression mutants may be subject to
higher-order metabolic perturbations due to feedback or com-
pensations in connected pathways, we assert that the 4-fold in-
crease in MIC due to increased expression of gltB is supportive of
the idea that azaserine, a mimic of the natural substrate of GltB,
inhibits this enzyme.
Examining a more sophisticated and tunable informatics
strategy, we turned to 3-D pharmacophore searching. Speciﬁ-
cally, we generated a common-feature pharmacophore model
for L-glutamateinDiscoveryStudio2.5.5.Thepharmacophore
consistedofapositiveionizablefeatureforthe-aminogroup,
a negative ionizable feature for the -carboxyl moiety, and a
hydrogen bond acceptor feature for the side chain carboxylate
TABLE 2 Essential molecules of the chorismate biosynthesis pathway in M. tuberculosis and their mimics
Essential molecule Molecule ID, % similarity, MIC90 for M. tuberculosis (g/ml), and structure of an analoga
3-Dehydroquinate 17699, 55, 14.7 52283. 56, 2.07 110597, 70, 7.1
3-Dehydro-shikimate 209508, 50, 12.0 398410, 52, 2.3 398407, 52, 4.6
Shikimate-3-phosphate 50320, 41, 73 170440, 42, 14.4 340891, 43, 10
5-Enolpyruvyl-shikimate-3-phosphate 340430, 52, 3.1 163046, 55 168409, 56
Chorismate 167369, 45. 0.98 340733, 50, 26 53251, 50, 10.16
a Representative essential molecules of the pathway for chorismate biosynthesis in M. tuberculosis and examples of existing analogs. An identiﬁcation provided by the CDD
database, percent similarity to the corresponding essential molecule, and MIC90 for M. tuberculosis are shown. The MIC90 data are compiled in the CDD database from various
laboratories. The percent inhibition of molecule 163046 at a 10 M concentration was 8.8%, and that for molecule 168409 was 48.6%.
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around the side chain carboxylate was “relaxed” from a nega-
tive ionizable feature to a hydrogen bond acceptor feature in
order to avoid returning diacids as hits, which in our experi-
ence fail to exhibit whole-cell activity due to the lack of M.
tuberculosis permeability. Azaserine, in addition to exhibiting
Tanimotosimilarityto L-glutamate,favorablyﬁtsthispharma-
cophore model, possessing chemical moieties mapping to all
three pharmacophoric elements and a FitValue (reﬂecting
goodness of ﬁt to the model) of 2.1. This 3-D model was uti-
lizedtosearchconformerdatabasesofcommercialcompounds
chosen from Asinex, Maybridge, and Microsource. The phar-
macophore model was selective, because, for example, only 130
out of 2,642 FDA-approved drugs and 199 out of 57,181 May-
bridge compounds ﬁt and were scored with a FitValue. Visual
inspection of hits afforded 12 molecules for purchase that were
assayed (Table 3 and see Table S4 in the supplemental material).
As a collection, all of these putative mimics maintain the
-carboxylgroupinclosespatialproximitytoabasicamine,while
displaying a variety of polar functionalities with hydrogen bond-
accepting ability. Among these compounds, JFD01307SC and
L-methionine-S-sulfoximine showed activity against M. tubercu-
losis, with MICs in the range of 8 to 16 g/ml and 8 to 12 g/ml,
respectively.Tooursurprise,weobservedthesusceptibilityofthe
M. tuberculosis strain overexpressing gltB to the two compounds
to be similar to that of the wild-type strain. We hypothesize that
the observed activity of JFD01307SC and L-methionine-S-
sulfoximinemayhaveresultedfromatargetthatissimilartoGltB,
or the compounds are metabolized into more than one active
molecule. L-Methionine-S-sulfoximine is known to inhibit glu-
tamine synthase in humans and M. tuberculosis (35). Given the
structural similarity of glutamine and glutamate and their shared
TABLE 3 Examples of biomolecules that are essential for the metabolism and survival of M. tuberculosis and their structural analogsa
Essential molecule and structure Structural analog
%
similarity
Activity against
M. tuberculosis
Reference
or source
L-Glutamate Azaserine 32 MIC  1 g/ml 15
L-Methionine-S-sulfoximineb 30 MIC  8–12 g/ml
JFD01307SCb 22 MIC  8–16 g/ml
UDP-N-acetylmuramoyl-L-alanyl-D-glutamyl-
meso-2,6-diaminopimelyl-D-alanyl-D-alanine
CDD-343074 58 50
Bleomycin 57 MIC  0.1 g/ml CDD database
Hydroxymethylbilane ChemDiv 4286-0015d 45 IC50  3.38 Mc CDD database
Porﬁmer 45 CDD database
a Examples of biomolecules essential for the metabolism and survival of M. tuberculosis and their structural analogs are shown as a proof of the principle that molecular mimics
with medicinal properties can be rapidly identiﬁed. Some of these molecules have known activities against M. tuberculosis. CDD stands for Collaborative Drug Discovery, a drug
database and mining software. % similarity was calculated in the CDD database using ChemAxon ﬁngerprints and Tanimoto similarity.
b Molecules identiﬁed by 3-D pharmacophore searching.
c IC50, 50% inhibitory concentration.
d MLSMR data set for dose response.
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L-methionine-S-sulfoximine may target enzymes involved in glu-
tamine biosynthesis.
Essential metabolites of the peptidoglycan, chorismate, and
tetrapyrrolepathwaysandtheirmimics.TheTanimotosimilar-
itysearchingmethodologywasutilizedtosearchtheCollaborative
DrugDiscoveryTBdatabaseformimicsoftheessentialmolecules
of the peptidoglycan, chorismate, and tetrapyrrole biosynthetic
pathways. The results for these searches are shown in Tables 1, 2
and 3. Clearly, the mimics exhibit a range of chemical structures
that in many cases do not appear to be obvious structural analogs
of the essential molecules. For example, the glycopeptide antibi-
otic bleomycin has 57% molecular similarity to UDP-N-
acetylmuramoyl-L-alanyl-D-glutamyl-meso-2,6-diaminopimelyl-
D-alanyl-D-alanine, commonly known as disaccharyl
pentapeptide, and a MIC of 0.1 g/ml (36). This study reported
that guinea pigs treated with bleomycin had smaller lesions and
fewer acid-fast bacilli than untreated guinea pigs and a prolonged
survival time. Future efforts will examine the inhibition of
Rv2153c (MT2212) by bleomycin in addition to its whole-cell
activity against an M. tuberculosis strain overexpressing this gene.
DISCUSSION
A powerful and widely accepted method for developing chemical
probes for and inhibitors of a target protein is to determine the
structure of the protein and identify or design molecules that ﬁt
the active site of the protein. Structure-based optimization of
these starting points by leveraging X-ray crystal structures of the
target essential gene product bound to the essential metabolite or
its close analogs would provide a starting point for developing
more potent molecules (37, 38). However, these enzyme inhibi-
tors may still lack whole-cell activity and in vivo efﬁcacy. This
approach also requires the structure of the protein to be known
and available. We assume that the fundamental knowledge of the
shape of the substrate for an essential enzyme can be used to infer
detailsofthebindingsiterequirements(39).Wehereinhavepro-
posedastrategyforleveragingtheessentialmoleculesofM.tuber-
culosis to arrive at potent antitubercular small molecules with sig-
niﬁcant promise as chemical probes that may ultimately inspire
preclinical drug candidates. Optimally, this involves choosing
mimics from a database of small-molecule inhibitors of M. tuber-
culosis growth, such as the CDD TB database.
This is a systematic approach for drug discovery which begins
with identiﬁcation of targets in the pathogen. As selection of can-
didate inhibitory compounds is based on the identities of veriﬁed
targets, the pathways affected and the likely mechanism of action
are known a priori. While we cannot discount the potential for
small-moleculeanalogsofessentialmetabolitesexhibitingafﬁnity
for other mycobacterial targets, attempts to maintain signiﬁcant
similarity to the essential metabolite should effectively minimize
this promiscuity. This might also be predicted by understanding
the 2-D or 3-D pharmacophore similarity to other metabolites of
the essential target mimic. This is a signiﬁcant advantage, since a
drug with a novel mechanism of action is a necessity for killing
those strains of M. tuberculosis that are resistant to one or more
current TB drugs.
Theexamplesofazaserine,JFD01307SC,and L-methionine-S-
sulfoximine provide a proof of principle that mimics of essential
metabolites, as identiﬁed through cheminformatic methods, may
represent effective molecules with anti-TB activity in vitro.I t
should be noted that gabapentin and nine additional molecules
with signiﬁcant Tanimoto and/or 3-D-pharmacophore-assessed
similarity to L-glutamate (see Table S4 in the supplemental mate-
rial)didnotshowactivityagainstwild-typeM.tuberculosisandthe
gltB-overexpressing strain in our study, illustrating our conclu-
sionthatmolecularmimicry,asjudgedbyTanimotosimilarityor
ﬁt (technically deﬁned as the FitValue in Discovery Studio) to a
givenpharmacophoremodelforametabolite,doesnotsingularly
meet the criteria for effective inhibition of the putative enzyme.
Further studies are necessary to probe the relationship between
activity against the intended biological target and the Tanimoto
similaritybetweentheassociatedmetaboliteanditsmimicsaswell
as the calculated ﬁt of mimics to the metabolite pharmacophore
model.Clearly,thedegreeofTanimotosimilarityisdependenton
the molecular ﬁngerprints chosen. We observed a range of pair-
wise Tanimoto similarities (25.6% to 48.8%) for L-glutamate and
azaserine using FCFP_6 or Molecular Design Limited (MDL) ﬁn-
gerprints, respectively. A best practice may involve sampling a
subsetofavailableﬁngerprintalgorithmsorusingamethodology,
like that from ChemAxon, as done in this study, where similarity
scoresconsistentlynearedthemidrange.Additionally,itisevident
that pharmacophore models are tunable, given the chemical fea-
turesonechoosestoincludeorignore.Thus,itisouranticipation
thatoptimizationofpharmacophoresearchmodelswillbeneces-
sary to further leverage our methodology for choosing mimics of
essential metabolites. This is neither unexpected nor completely
dissimilar from what we have learned in high-throughput screen-
ing campaigns, where the choice of compound library and assay
are critical for success.
These data illustrate that a single cheminformatics method is
not universally applicable in predicting the speciﬁcity of a syn-
thetic molecule for the target essential enzyme. Approximately
40% of genes of M. tuberculosis have yet to be functionally anno-
tated (16). Our lack of information on the pathways constituted
by enzymes encoded by these hypothetical genes means that a
large number of metabolites cannot be accounted for at this stage
of study. Identiﬁcation of all metabolites of M. tuberculosis is a
major hurdle that diminishes the ability of our approach to iden-
tify a molecular mimic with high speciﬁcity to the target essential
enzyme. The potential does exist, however, for the implementa-
tion of medicinal chemistry techniques to optimize these initially
chosen molecular mimics for selectivity as well as potency. These
medicinal chemistry operations would be part of a more global
optimization of the chemical structure of the mimic, with regard
topharmacokinetic,pharmacodynamic,andsafetyproﬁles,inor-
der to transition from chemical probe to lead molecule and ulti-
mately to drug candidate. Additionally, cheminformatic tech-
niques may have to be developed and leveraged to choose mimics
for their similarity to a given metabolite and dissimilarity to all
other metabolites.
Thetime-testedmethodofscreeningforgrowthinhibitorshas
also been a useful approach in ﬁnding TB drugs (for example, the
recentdiscoveriesofR207910andOPC-67683),butoftenthemo-
lecular target of the inhibitor remains unknown at the end of a
successfulscreen(40,41).Indeed,Andriesetal.resortedtowhole-
genomesequencingofstrainssusceptibleandresistanttoR207910
in order to ascertain that its target is likely to be a subunit of M.
tuberculosis ATP synthase encoded by atpE (40). Our approach
obviates the initial requirement for identiﬁcation of a molecular
target(s) and thereby accelerates the drug discovery process, re-
Targeting Essential Metabolic Pathways
January/February 2011 Volume 2 Issue 1 e00301-10
® mbio.asm.org 7ducing the associated costs. It should be noted that it is unlikely
thatthemolecularmimicrymethodshownherewouldhaveiden-
tiﬁed R207910, as this compound targets the Fo subunit of ATP
synthase. This subunit in itself is not an enzyme and does not
generate an essential metabolite. Another limitation of our ap-
proach is that a molecule that mimics an essential metabolite and
inhibits the corresponding essential enzyme may not be active
against the whole-cell organism for numerous reasons, including
lack of penetration, active efﬂux or metabolism, and clearance by
the organism or the host.
Our approach also allows for selective targeting of the patho-
gen. Selection of pathways and targets that are present only in the
pathogenreducestheprobabilityoftoxicitytothehost.According
to our analysis using the BioCyc pathway/genome database
(PGDB),thethreepathwaysstudiedinthiswork,namely,biosyn-
thesis of peptidoglycan, tetrapyrroles, and chorismate, are absent
inthehumanhost.Yetitshouldbenotedthatthereisapossibility
for cross toxicity to the host itself or for cross toxicity from unin-
tended toxicity to the resident microbiome in the host. Mycobac-
terium bovis, another organism that belongs to the same genus as
M. tuberculosis, also possesses the pathways for biosynthesis of
peptidoglycan, tetrapyrroles, and chorismate. This organism
causes bovine tuberculosis and, thus, is of major concern to the
cattle industry. Using the BioCyc database, we compared the ge-
nomes of M. bovis and Bos taurus, domestic cattle, and found that
the three pathways are present only in the pathogen. Therefore,
developingdrugstotargetthesepathwaysislikelytohaveselective
toxicity to the pathogen when administered to the host to treat
mycobacterial infections.
We have elaborated an intermediate strategy between high-
throughput screening and rational structure-based drug design,
leveraging knowledge of the essential M. tuberculosis genes and
consequently essential pathways and their associated enzymes to
arrive at essential molecules and their analogs. Our deﬁnition of
the essential molecules of M. tuberculosis and their partial enu-
meration are clearly reliant on the assumptions made to establish
the essential genes of M. tuberculosis (6, 15). We assert that a col-
lection of these essential molecules and of others that have yet to
be identiﬁed is what ultimately is required for determining the
essential metabolic functions of the organism. A perturbation in
the concentration or availability of these molecules is likely to
adverselyaffecttheorganism’sviability.Arationalwaytoalterthe
critical concentrations of these essential molecules in vivo is to
utilize a compound that mimics its structural and chemical prop-
ertiesasacompetitiveinhibitoroftheessentialenzyme.Ananalog
that is able to strongly bind to the active site of the enzyme and
thereby prevent interaction with the native essential molecules is
likely to competitively inhibit the function and eventually lead to
stasis or the death of the organism. A continued evolution of this
setofgenesandpathwaysmayberequisitetomoreaccuratelyand
comprehensively reveal the essential targets under a given set of
growth conditions deemed to be relevant for a speciﬁc disease
state. Of course, a scenario in which an approved drug is found to
beametabolitemimiccouldpresentitself,andthroughrepurpos-
ing, the mimic could represent a novel antitubercular agent with
little if any need for optimization prior to clinical trials.
MATERIALS AND METHODS
Bacterial strains, mutagenesis, and gene essentiality. A
clinicalisolateofM.tuberculosis,CDC1551,wasusedasthehostorganism.It
was grown in Middlebrook 7H9 medium (Difco) supplemented with 0.2%
glycerol,10%(vol/vol)oleicacid-albumin-dextrose-catalase(OADC;Becton
Dickinson), and 0.05% Tween 80 at 37°C. Mutagenesis using the Himar1
transposon, isolation, and genotyping of mutants were undertaken as de-
scribed in our previous work (15). Any gene in which we identiﬁed a
transposon insertion disruption was deemed nonessential for in vitro
survival. Once these initial nonessential and essential gene lists were
established, three ﬁlter operations were performed to reﬁne both
groups. The ﬁrst ﬁlter, designated here the 5= 80%/3= 100-bp test,
returned nonessential genes with distal insertions within 20% (for
small genes) or 100 bp of the 3= end to the essential list because such
insertions may not signiﬁcantly affect the product’s function. The sec-
ond ﬁlter, called the operon test, reclassiﬁed essential genes as nones-
sential if they belonged to an operon that was disrupted in a more
proximalgene.Therefore,suchgeneswerenotessentialfortheinvitro
growth of those mutants. The 4,590-bp gltB open reading frame was
cloned from M. tuberculosis CDC1551 genomic DNA by PCR using
primers MT3974-P1 (5=-GGGGACAAGTTTGTACAAAAAAGCAGG
CTTAAGGAGGTGTGGGTATGACGCCTAAG-3=) and MT3974-P2
(5=-GGGGACCACTTTGTACAAGAAAGCTGGGTATCAGCCATGC
GCAGCCGCCATG-3=). A fully sequenced and mutation-free clone
was recombined into the Escherichia coli-M. tuberculosis Gateway-
compatible knock-in shuttle vector pGS400K (a variant of pGS400H
which features kanamycin selection [42]). M. tuberculosis CDC1551
was transformed with the resulting plasmid, pGS400K-gltB(tb), by
usingstandardtechniques(43),andtransformantswereobtainedafter
3 to 4 weeks of growth on 7H10 plates (Becton Dickinson) containing
20 g/ml kanamycin (Sigma). A gltB knock-in strain was grown in
Middlebrook 7H9 broth, total RNA was isolated using standard tech-
niques (44), and the expression of gltB was quantiﬁed by real-time
RT-PCR.
Determination of essential metabolic pathways, essential mole-
cules, and analogs. The BioCyc PGDB also included a database of pre-
dicted metabolic pathways in M. tuberculosis, along with the genes in-
volvedineachpathway(17).Thisdatabasewasusedasastartingpointfor
determiningtheessentialityofeachpathway.TheBioCycPGDBwasused
to map the putative reactions catalyzed by enzymes that were assessed to
beessentialinouranalysis.Thedatabasecollectsthemolecularstructures
and formulas of the reactants and products for each enzyme. This infor-
mation was used to generate a database of putative essential molecules of
M. tuberculosis which comprise the reactants and products of enzymes
that are essential for the growth and survival of the organism.
Determination of MICs. We determined the MICs of all compounds
inthisstudyusingthebrothdilutionmethod(34).Forthis,weinoculated
105 wild-type M. tuberculosis bacilli and bacilli of the gltB knock-in strain
separately in 2.5 ml of 7H9 broth without detergent and added the com-
poundsby2-foldserialdilutions.Weincubatedtheseculturesat37°Cand
evaluatedthemforgranulation,ameasureofgrowth,byvisualinspection
at 7 and 14 days. For those samples with diminished growth compared to
that of a no-drug control, we determined numbers of CFU.
CDD database. Structural analogs or mimics of the putative essential
moleculeswerethencompiledbyconductingsimilaritysearchesusingthe
CDD TB database (Collaborative Drug Discovery Inc., Burlingame, CA),
which has been described previously (27), with applications for collabo-
rative research (28). This consists of several TB screening data sets col-
lected and uploaded from SDF ﬁles and mapped to custom protocols,
including the data sets of the NIAID (n  3,748), GVK BIO (n  2,880)
(45), TAACF (n  812), and MLSMR (n  220,463) (45), known TB
drugs(n13)(38),TBcandidatesofBallelletal.(n48)(46),andSAR
data collated from the TB literature (n  6,770) (27). In addition, the
CDDdatabasealsoincludesFDA-approveddrugs(n2,815)andvendor
molecule libraries (27).
3-Dpharmacophore.3-Dcomputationalmolecularmodelingstudies
were carried out using Catalyst in Discovery Studio 2.5.5 (Accelrys, San
Diego, CA). A common-feature (HipHop) pharmacophore model was
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the arrangement of key features that are important for biological activity
and have been widely described (47, 48). Ten pharmacophores were cre-
atedinDiscoveryStudio(notethatallhadslightlydifferentfeatures,etc.).
Pharmacophore 4 consisted of a negative ionizable, a positive ionizable,
and a hydrogen bond acceptor feature (Fig. S2).
The database of FDA-approved drugs (n  2,815) from the CDD
database was downloaded as an SDF ﬁle and converted to a 3-D Catalyst
database after generating up to 100 molecule conformations with the
FAST conformer generation method, with a maximum energy threshold
of 20 kcal/mol. In addition, the Maybridge vendor database (n  57,181)
wasgeneratedinthreedimensionsinthesameway.Thecommon-feature
pharmacophore model was then applied to screen these databases using
theFASTsearchmethodinthesamemanneraspreviouslydescribed(49).
The quality of the molecule mapping to the pharmacophore was deter-
mined by the FitValue, which is dependent on the proximity of a com-
pound to the pharmacophore feature centroids and the weights assigned
to each centroid, where a higher FitValue represents a better ﬁt. Com-
pounds were then selected for purchase and testing.
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